Zachary Clifford Landman, MD
Preventive Medicine · Berkeley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 7
Offices
7 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: 057004 · Alta Bates Summit Medical Center - Alta Bates Camp · Eden Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Landman’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A138740 · Current
Licensed to practise in California · since 2015 · expires 2027-08-31 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$364,426
Medicare paid this office $364,426 for 459 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 334 | $131,483 | $114 |
| New patient visit (45+ min) | 205 | $30,811 | $150 |
| Botox | 11 | $25,336 | None |
| Insertion of peripheral nerve neurostimulator electrode through skin | 47 | $23,221 | $221 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 133 | $19,179 | $125 |
See all 25 services
| Return visit (30+ min) | 334 | $131,483 | $114 |
| New patient visit (45+ min) | 205 | $30,811 | $150 |
| Botox | 11 | $25,336 | None |
| Insertion of peripheral nerve neurostimulator electrode through skin | 47 | $23,221 | $221 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 133 | $19,179 | $125 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 63 | $14,410 | $113 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 319 | $11,866 | $15 |
| Insertion of spinal neurostimulator electrode array through skin | 17 | $11,329 | $283 |
| Long return visit (40+ min) | 48 | $11,168 | $164 |
| Short return visit (20+ min) | 87 | $10,719 | $87 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 32 | $8,750 | $250 |
| Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | 15 | $7,468 | None |
| New patient visit (60+ min) | 37 | $7,096 | $192 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 36 | $6,317 | $113 |
| Injection of anesthetic agent and/or steroid into knee nerve branch using imaging guidance | 21 | $6,271 | $251 |
| Injection of trigger points, 3 or more muscles | 65 | $5,389 | $53 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 73 | $3,694 | $45 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 11 | $3,589 | $138 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 35 | $3,372 | $61 |
| Injection of substance into middle or upper spine canal using imaging guidance | 30 | $2,814 | $88 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 33 | $2,744 | $76 |
| Ultrasonic guidance for needle placement | 19 | $1,212 | $55 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 70 | $836 | $10 |
| Injection, methylprednisolone acetate, 1 mg | 58 | $311 | None |
| Injection, methylprednisolone acetate, 40 mg | 24 | $131 | None |
Who their Medicare patients are
459 Original Medicare patients in 2024. Average age 74 · Under 65 12% · 85 and older 11% · Women 72% · Also on Medicaid 21% · Health risk score 1.37. Above the middle of the specialty; the typical preventive medicine clinician is at 1.23.
Conditions among them: High blood pressure 71% · Depression 32% · Chronic kidney disease 27% · Diabetes 25% · Cancer 18% · Coronary heart disease 17% · Heart failure 16% · COPD 16% · Atrial fibrillation 15% · Stroke 7% · Dementia 5%.
The office billed $1,871,337, Medicare allowed $474,501 and paid $364,426; for 12,378 services of 62 kinds; $34,081 of it was for drugs given in the office and $330,345 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 459 | 12,378 | 74 | 1.37 | $1,871,337 | $364,426 |
| 2023 | 330 | 5,095 | 73 | 1.29 | $1,341,346 | $264,541 |
| 2022 | 137 | 439 | 72 | 1.56 | $175,490 | $40,818 |
| 2021 | 81 | 101 | 72 | 1.29 | $25,091 | $4,993 |
| 2020 | 354 | 575 | 74 | 1.11 | $130,864 | $32,942 |
| 2019 | 618 | 1,218 | 73 | 1.21 | $265,261 | $67,512 |
| 2018 | 617 | 1,126 | 73 | 1.09 | $255,835 | $69,343 |
| 2017 | 142 | 191 | 72 | 1.15 | $41,533 | $11,804 |
| 2016 | 39 | 47 | 74 | 0.72 | $11,783 | $3,437 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 24 services
| Return visit (30+ min) | 242 | $87,097 | $116 |
| Long return visit (40+ min) | 99 | $32,538 | $165 |
| New patient visit (45+ min) | 166 | $23,587 | $142 |
| New patient visit (60+ min) | 57 | $11,333 | $199 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 72 | $10,285 | $122 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 51 | $9,605 | $116 |
| Insertion of spinal neurostimulator electrode array through skin | 11 | $8,591 | $286 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 21 | $6,481 | $196 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 35 | $6,466 | $120 |
| Removal of bone from lower spine for decompression of nerve tissue using imaging guidance, accessed through the skin | 12 | $6,396 | $533 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 32 | $3,460 | $68 |
| Short return visit (20+ min) | 31 | $3,120 | $84 |
| Injection of substance into middle or upper spine canal using imaging guidance | 27 | $2,923 | $97 |
| Injection of trigger points, 3 or more muscles | 41 | $2,884 | $52 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 46 | $2,332 | $45 |
| Injection of upper or middle spine facet joint using imaging guidance, single level | 11 | $2,266 | $119 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 20 | $1,830 | $59 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 18 | $1,810 | $91 |
| Ultrasonic guidance for needle placement | 19 | $1,461 | $58 |
| Evaluation of psychological test, first hour | 12 | $1,317 | $110 |
| Injection of upper or middle spine facet joint using imaging guidance, second level | 11 | $1,276 | $67 |
| Injection of substance into lower spine canal using imaging guidance | 12 | $935 | $78 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 54 | $866 | $11 |
| Injection, methylprednisolone acetate, 40 mg | 64 | $537 | None |
2022: 9 services
| Return visit (30+ min) | 63 | $11,900 | $121 |
| New patient visit (45+ min) | 52 | $7,973 | $153 |
| Long return visit (40+ min) | 24 | $5,238 | $169 |
| New patient visit (60+ min) | 18 | $3,691 | $205 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 14 | $1,726 | $123 |
| Injection of trigger points, 3 or more muscles | 12 | $920 | $57 |
| Short return visit (20+ min) | 11 | $701 | $64 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $304 | $23 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 14 | $184 | $11 |
2021: 3 services
| Return visit (30+ min) | 29 | $1,749 | $58 |
| New patient visit (30+ min) | 16 | $542 | $34 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 17 | $421 | $25 |
2020: 8 services
| Return visit (30+ min) | 140 | $12,074 | $84 |
| New patient visit (30+ min) | 126 | $10,522 | $84 |
| Short return visit (20+ min) | 66 | $4,319 | $62 |
| New patient visit (45+ min) | 12 | $1,208 | $101 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 22 | $281 | $13 |
| Detection test by immunoassay with direct visual observation for influenza virus | 17 | $276 | $16 |
| Injection of drug or substance under skin or into muscle | 15 | $183 | $12 |
| Automated urinalysis test | 48 | $109 | $2 |
2019: 14 services
| Return visit (30+ min) | 238 | $23,148 | $87 |
| New patient visit (30+ min) | 185 | $16,331 | $88 |
| Short return visit (20+ min) | 125 | $7,605 | $58 |
| New patient visit (45+ min) | 57 | $6,422 | $113 |
| Long return visit (40+ min) | 27 | $3,676 | $131 |
| Detection test by immunoassay with direct visual observation for influenza virus | 55 | $884 | $16 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 54 | $828 | $15 |
| Inhalation treatment for airway obstruction or sputum production | 37 | $747 | $18 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 37 | $599 | $16 |
| Injection of drug or substance under skin or into muscle | 32 | $510 | $16 |
| Automated urinalysis test | 79 | $205 | $2 |
| Injection, ceftriaxone sodium, per 250 mg | 13 | $18 | None |
| Injection, ketorolac tromethamine, per 15 mg | 15 | $12 | None |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 37 | $5 | None |
2018: 15 services
| Return visit (30+ min) | 220 | $23,986 | $92 |
| New patient visit (30+ min) | 170 | $14,344 | $84 |
| Short return visit (20+ min) | 187 | $11,113 | $56 |
| New patient visit (45+ min) | 39 | $5,343 | $137 |
| Long return visit (40+ min) | 21 | $2,731 | $130 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 56 | $893 | $16 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 42 | $664 | $16 |
| Detection test by immunoassay with direct visual observation for influenza virus | 31 | $503 | $16 |
| Injection of drug or substance under skin or into muscle | 19 | $364 | $19 |
| Inhalation treatment for airway obstruction or sputum production | 16 | $333 | $18 |
| Automated urinalysis test | 80 | $244 | $3 |
| Blood glucose (sugar) test performed by hand-held instrument | 12 | $39 | $3 |
| Urinalysis, manual test | 11 | $38 | $3 |
| Injection, ketorolac tromethamine, per 15 mg | 13 | $12 | None |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 15 | $2 | None |
2017: 3 services
| Short return visit (20+ min) | 73 | $4,967 | $65 |
| New patient visit (30+ min) | 31 | $2,459 | $79 |
| Return visit (30+ min) | 22 | $2,036 | $93 |
2016: 2 services
| New patient visit (30+ min) | 21 | $1,924 | $92 |
| Short return visit (20+ min) | 12 | $786 | $66 |
Drugs they prescribed that Part D paid
$110,070
Pharmacies billed $110,070 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 27% of their Part D prescriptions (710 of 2,621) in 2024. A higher opioid share than 9 in 10 peers; the typical preventive medicine clinician is at 0%. Long-acting opioids: 18% of their opioid prescriptions.
2,553 generic and 68 brand-name prescriptions · $110,070 in drug cost · 17 antibiotic prescriptions to 13 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Buprenorphine | 83 | $16,362 | $197 |
| Belbuca | 12 | $11,234 | $936 |
| Lidocaine | 42 | $7,077 | $169 |
| Gabapentin | 450 | $5,381 | $12 |
| Hydrocodone-Acetaminophen | 266 | $5,227 | $20 |
See all 28 drugs
| Buprenorphine | 83 | $16,362 | $197 |
| Belbuca | 12 | $11,234 | $936 |
| Lidocaine | 42 | $7,077 | $169 |
| Gabapentin | 450 | $5,381 | $12 |
| Hydrocodone-Acetaminophen | 266 | $5,227 | $20 |
| Pregabalin | 195 | $5,032 | $26 |
| Duloxetine | 188 | $4,365 | $23 |
| Buprenorphine-Naloxone | 23 | $4,184 | $182 |
| Oxycodone-Acetaminophen | 148 | $3,788 | $26 |
| Celecoxib | 74 | $3,435 | $46 |
| Naloxone | 38 | $2,076 | $55 |
| Tizanidine | 202 | $1,778 | $9 |
| Nortriptyline | 85 | $1,029 | $12 |
| Oxycodone | 73 | $949 | $13 |
| Cyclobenzaprine | 44 | $901 | $20 |
| Diclofenac | 29 | $849 | $29 |
| Buprenorphine | 36 | $683 | $19 |
| Tramadol | 84 | $521 | $6 |
| Nabumetone | 38 | $421 | $11 |
| Topiramate | 49 | $410 | $8 |
| Meloxicam | 131 | $342 | $3 |
| Baclofen | 26 | $322 | $12 |
| Venlafaxine Hcl Er | 17 | $188 | $11 |
| Ondansetron Odt | 11 | $164 | $15 |
| Trazodone | 15 | $162 | $11 |
| Methylprednisolone | 24 | $136 | $6 |
| Clonidine | 13 | $110 | $8 |
| Lorazepam | 16 | $38 | $2 |
Year by year
| 2024 | 2,621 | 405 | 27% (710) | 3% | $110,070 |
| 2023 | 1,632 | 276 | 28% (454) | 1% | $59,507 |
| 2022 | 341 | 135 | 25% (86) | 4% | $14,906 |
| 2021 | 158 | 83 | 15% (24) | None | $3,567 |
| 2020 | 214 | 167 | None | 12% | $4,281 |
| 2019 | 413 | 289 | None | 15% | $11,132 |
| 2018 | 456 | 312 | None | 16% | $15,549 |
| 2017 | 101 | 75 | None | 20% | $4,224 |
| 2016 | 23 | 20 | None | None | $969 |
| 2013 | 26 | 20 | 50% (13) | None | $660 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 20 drugs
| Buprenorphine | 27 | $7,152 | $265 |
| Celecoxib | 61 | $4,452 | $73 |
| Pregabalin | 111 | $4,192 | $38 |
| Lidocaine | 20 | $3,875 | $194 |
| Hydrocodone-Acetaminophen | 207 | $3,807 | $18 |
| Gabapentin | 210 | $3,545 | $17 |
| Naloxone | 41 | $3,024 | $74 |
| Duloxetine | 144 | $2,682 | $19 |
| Oxycodone-Acetaminophen | 87 | $2,522 | $29 |
| Diclofenac | 29 | $2,120 | $73 |
| Buprenorphine | 63 | $1,653 | $26 |
| Tizanidine | 119 | $1,126 | $9 |
| Nortriptyline | 48 | $1,043 | $22 |
| Baclofen | 20 | $685 | $34 |
| Oxycodone | 58 | $636 | $11 |
| Tramadol | 56 | $613 | $11 |
| Meloxicam | 98 | $466 | $5 |
| Bupropion Xl | 16 | $204 | $13 |
| Methylprednisolone | 11 | $95 | $9 |
| Lorazepam | 20 | $22 | $1 |
2022: 7 drugs
| Pregabalin | 32 | $2,039 | $64 |
| Duloxetine | 33 | $767 | $23 |
| Hydrocodone-Acetaminophen | 37 | $680 | $18 |
| Gabapentin | 38 | $576 | $15 |
| Diclofenac | 12 | $324 | $27 |
| Oxycodone | 13 | $287 | $22 |
| Tizanidine | 28 | $178 | $6 |
2021: 1 drug
| Hydrocodone-Acetaminophen | 12 | $267 | $22 |
2020: 3 drugs
| Diclofenac | 17 | $398 | $23 |
| Doxycycline Monohydrate | 22 | $267 | $12 |
| Cephalexin | 21 | $108 | $5 |
2019: 12 drugs
| Ventolin Hfa | 11 | $631 | $57 |
| Diclofenac | 14 | $375 | $27 |
| Azithromycin | 38 | $271 | $7 |
| Doxycycline Monohydrate | 25 | $260 | $10 |
| Nitrofurantoin Mono-Macro | 16 | $245 | $15 |
| Cephalexin | 31 | $184 | $6 |
| Amoxicillin-Clavulanate Potass | 18 | $149 | $8 |
| Mupirocin | 15 | $131 | $9 |
| Polymyxin B Sul-Trimethoprim | 12 | $94 | $8 |
| Prednisone | 29 | $80 | $3 |
| Sulfamethoxazole-Trimethoprim | 15 | $75 | $5 |
| Amoxicillin | 11 | $72 | $7 |
2018: 11 drugs
| Flovent Hfa | 18 | $5,556 | $309 |
| Oseltamivir Phosphate | 12 | $1,059 | $88 |
| Diclofenac | 15 | $521 | $35 |
| Azithromycin | 47 | $315 | $7 |
| Cephalexin | 52 | $255 | $5 |
| Amoxicillin-Clavulanate Potass | 23 | $209 | $9 |
| Triamcinolone Acetonide | 17 | $103 | $6 |
| Mupirocin | 11 | $101 | $9 |
| Doxycycline Monohydrate | 12 | $95 | $8 |
| Amoxicillin | 19 | $94 | $5 |
| Prednisone | 15 | $66 | $4 |
2017: 2 drugs
| Cephalexin | 12 | $97 | $8 |
| Sulfamethoxazole-Trimethoprim | 12 | $35 | $3 |
Money from drug and device companies
$792 in 2025
| 2025 | 2 | 18 | None | $792 |
| 2024 | 5 | 9 | None | $365 |
| 2023 | 4 | 9 | None | $629 |
| 2022 | 3 | 10 | None | $1,111 |
| 2021 | 4 | 8 | None | $1,347 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Intracept | $579 | 16 payments
|
| SPR Therapeutics | Sprint Pns System | $213 | 2 payments
|
See all 18 published payments
| Boston Scientific | Meals · 2025-10-07 | Wavewriter Alpha Prime 16 | $13 |
| Boston Scientific | Meals · 2025-10-04 | Intracept | $24 |
| Boston Scientific | Meals · 2025-10-04 | Intracept | $149 |
| Boston Scientific | Meals · 2025-10-02 | Wavewriter Alpha Prime 16 | $15 |
| Boston Scientific | Meals · 2025-09-30 | Wavewriter Alpha Prime 16 | $14 |
| Boston Scientific | Meals · 2025-09-23 | Wavewriter Alpha Prime 16 | $8 |
| Boston Scientific | Meals · 2025-09-17 | Wavewriter Alpha Prime 16 | $13 |
| SPR Therapeutics | Meals · 2025-09-02 | Sprint Pns System | $125 |
| Boston Scientific | Meals · 2025-08-20 | Wavewriter Alpha Prime 16 | $12 |
| Boston Scientific | Meals · 2025-08-15 | Wavewriter Alpha Prime 16 | $17 |
| Boston Scientific | Meals · 2025-08-04 | Wavewriter Alpha Prime 16 | $43 |
| Boston Scientific | Meals · 2025-07-30 | Wavewriter Alpha Prime 16 | $84 |
| Boston Scientific | Meals · 2025-07-28 | Intracept | $82 |
| Boston Scientific | Meals · 2025-06-27 | Wavewriter Alpha Prime 16 | $13 |
| Boston Scientific | Meals · 2025-06-13 | Wavewriter Alpha Prime 16 | $15 |
| SPR Therapeutics | Meals · 2025-05-30 | Sprint Pns System | $88 |
| Boston Scientific | Meals · 2025-05-21 | Wavewriter Alpha Prime 16 | $29 |
| Boston Scientific | Meals · 2025-02-20 | Intracept | $49 |
See earlier years (2024, 2023, 2022, 2021)
2024: $365
| SPR Therapeutics | Sprint Pns System | $142 | 3 payments
|
| Boston Scientific | Wavewriter Alpha Prime 16 | $90 | 2 payments
|
| Saluda Medical Americas | Evoke | $70 | 1 payment
|
| Nevro | Senza | $39 | 2 payments
|
| Abbott Laboratories | Eterna | $24 | 1 payment
|
2023: $629
| Boston Scientific | Wavewriter Alpha Prime 16 | $229 | 5 payments
|
| SPR Therapeutics | Sprint Pns System | $211 | 2 payments
|
| Relievant Medsystems | Intracept | $165 | 1 payment
|
| Nevro | Senza | $23 | 1 payment
|
2022: $1,111
| Boston Scientific | Wavewriter Alpha Prime 16 | $633 | 4 payments
|
| Nevro | Omnia | $265 | 4 payments
|
| SPR Therapeutics | Sprint Pns System | $213 | 2 payments
|
2021: $1,347
| Nevro | Omnia | $969 | 4 payments
|
| SPR Therapeutics | Sprint Pns System | $139 | 2 payments
|
| Nalu Medical | Nalu Neurostimulation System | $123 | 1 payment
|
| Boston Scientific | General Pain Management | $116 | 1 payment
|
Professional record
- NPI
- 1780947408
- Licence
- CA A138740California A138740: Current · expires 2027-08-31
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 208VP0014X (208VP0014X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2012-06-18
- NPI last updated
- 2023-12-07
- NPI record certified
- 2023-12-07
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 20101 Lake Chabot Rd, Castro Valley, CA, 94546